Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA polymorphisms in South Tunisian systemic sclerosis patients: a case-control study.

Clinical rheumatology·2025
Same author

Constrictive, calcific pericarditis in a systemic sclerosis patient.

Vascular diseases (Paris, France)·2025
Same author

Dacryoadenitis: do not forget ANCA vasculitis.

Romanian journal of ophthalmology·2024
Same author

[Aspirin and prevention of the recurrence of venous thromboembolism].

Annales de cardiologie et d'angeiologie·2024
Same author

Recurrent intra-cardiac thrombosis: A rare manifestation of Behçet's disease.

Journal de medecine vasculaire·2024
Same author

Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.

Romanian journal of internal medicine = Revue roumaine de medecine interne·2023

Related Experiment Video

Updated: Jul 8, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

[Hypomania under corticotherapy. About 50 cases].

Noureddine Ayadi1, Mohamed Rami Cheikhrouhou, Manel Kechaou

  • 1Service de psychiatrie A, CHU Hédi Chaker, Sfax, Tunisie. nour13632004@yahoo.fr

Therapie
|January 22, 2008
PubMed
Summary

Corticosteroid therapy can cause hypomania in 28% of patients, particularly those with lupus. Early screening using scales like the Angst scale is crucial for preventing complications.

Related Experiment Videos

Last Updated: Jul 8, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Area of Science:

  • Psychiatry
  • Endocrinology

Context:

  • Corticosteroid therapy is widely used for various inflammatory and autoimmune conditions.
  • Psychiatric complications, including hypomania, are potential adverse effects of corticosteroid treatment.

Purpose:

  • To determine the prevalence of hypomania as a complication of corticotherapy.
  • To discuss the clinical and etiopathogenic aspects of corticosteroid-induced hypomania.
  • To emphasize the importance of screening for hypomania in patients receiving corticosteroids.

Summary:

  • A study involving 50 patients on corticotherapy revealed a 28% prevalence of hypomania.
  • Hypomania occurred more frequently in patients with lupus (38.89%) compared to others (21.86%).
  • Symptom onset was typically within the first month of treatment, with an average prednisone dosage of 60-100 mg/day.

Impact:

  • Highlights the underestimation of psychiatric issues in patients on oral corticotherapy.
  • Advocates for active screening using questionnaires and scales like the Angst scale.
  • Stresses the need for secondary and tertiary prevention of hypomania to mitigate complications.